Diagnosing Dementia with Lewy Bodies – Characterizing the prevalence and underlying relationships between core and supportive clinical features
Objective: To characterize the interrelationship between core and supportive features of Dementia with Lewy Bodies, and identify optimal methods for their detection to inform better…Accelerometer-Based Gait Analysis for Patients with Parkinson’s Disease
Objective: The study is to develop an accelerometer-based gait analysis for the patients with Parkinson’s disease, which would provide timely complete gait information following the…Quantification of regional iron content with Susceptibility Weighted Imaging in Huntington Disease Expansion Gene Carriers
Objective: To assess brain iron content measured with SWI-MRI in HD gene expansion carriers (HDGECs). Background: Huntington’s Disease (HD) results in extensive neuronal cell loss,…Normative Curves for Selected Unified Huntington Disease Rating Scale Measures
Objective: To examine the effects of natural aging for those without Huntington disease (HD) gene expansion and to develop normative curves by age, sex, and…Subcortical atrophy is an early event in Huntington’s disease
Objective: To determine whether brain regional volumes are associated with clinical symptoms in premanifest and manifest Huntington’s disease (HD). Background: Striatal atrophy has been considered a…Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality
Objective: We sought to analyze the mortality and the causes of death of 105 patients with Parkinson disease (PD) treated with levodopa-carbidopa intestinal gel (LCIG)…Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)
Objective: To evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). Background: LID is…Improvements in gait deficits with peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study
Objective: Quantify changes in gait parameters in patients with Parkinson’s disease (PD) who underwent autologous peripheral nerve grafts implantation (surgical deployment of the Schwann cells…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Objective: To demonstrate the adverse impact of non-medical switching on patient care. Background: Non-medical switching (NMS) is a policy under which insurers or their pharmacy…
- « Previous Page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- …
- 217
- Next Page »